ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing

09 Feb, 2021

ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing
Photo by Ilya Pavlov on Unsplash

– ImmunoMet Therapeutics received IND clearance and orphan drug designation from the U.S. FDA for IM156 in idiopathic pulmonary fibrosis (IPF).
– The Company also announced the closing of $7.0M in new financing by both existing and new investors that will be used, in part, to fund the Phase 1 program.
– The Company plans to initiate a single-site U.S. Phase 1 study in 32 healthy volunteers designed to characterize the safety, tolerability, pharmacokinetics, and effects of IM156 in Q1 2021.
– Data from this Phase 1 study will inform the design of a Phase 2 trial in patients with IPF.

Biopharma Biotechnology Health Care North America Pharmaceutical Therapeutics
Crunchbase icon

Content report

The following text will be sent to our editors: